SABCS 2021 Conference Coverage on VuMedi


 

SABCS 2021 Update on Samuraciclib, a First-in-Class, Oral, Selective Inhibitor of CDK7, in Combination With Fulvestrant in Advanced HR+/HER2- BC

333 views
December 20, 2021
Comments 0
Login to view comments. Click here to Login